Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen
Introduction: Toxoplasma gondii (T. gondii) is distributed worldwide and infects most species. The serious incidence and severe or fatal injury caused by T. gondii infection clearly indicates the necessity for the event of a vaccine. The current study goals were to evaluate serological applications...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ilam University of Medical Sciences
2017-06-01
|
| Series: | Journal of Basic Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://jbrms.medilam.ac.ir/browse.php?a_code=A-10-168-2&slc_lang=en&sid=1 |
| _version_ | 1818260684475990016 |
|---|---|
| author | Fatemeh Keshavarzi Parviz Ashtari Pirooz Ebrahimi |
| author_facet | Fatemeh Keshavarzi Parviz Ashtari Pirooz Ebrahimi |
| author_sort | Fatemeh Keshavarzi |
| collection | DOAJ |
| description | Introduction: Toxoplasma gondii (T. gondii) is distributed worldwide and infects most species. The serious incidence and severe or fatal injury caused by T. gondii infection clearly indicates the necessity for the event of a vaccine. The current study goals were to evaluate serological applications of Toxoplasma gondiirhoptry protein 1 (ROP1) antigen.
Materials and methods: We created a polymer vaccine by using the eukaryotic plasmid, pROP1. Purification by one-step metal affinity chromatography allowed recovery of milligram amounts of purified recombinant proteins per liter of culture. The quality of this matter for diagnosing of human infections was provided and tested on 77 serum samples which were obtained during routine diagnostic tests. A panel of 20 serum samples from patients with acute toxoplasmosis was compared to a panel of 35 serum samples from individuals with chronic toxoplasmosis.
Results: Results of the study indicated that antibodies detected from patients with acute and chronic infections were 96% and 17%, respectively, by using of pROP1 recombinant antigen.
Conclusion: According to the present study an immunoglobulin G antibody against ROP1 antigen is made throughout the acute stage of toxoplasmosis infection, but not in the chronic phase of toxoplasmosis. |
| first_indexed | 2024-12-12T18:35:15Z |
| format | Article |
| id | doaj.art-480514b01b5a465aab86e57e3b522054 |
| institution | Directory Open Access Journal |
| issn | 2383-0506 2383-0972 |
| language | English |
| last_indexed | 2024-12-12T18:35:15Z |
| publishDate | 2017-06-01 |
| publisher | Ilam University of Medical Sciences |
| record_format | Article |
| series | Journal of Basic Research in Medical Sciences |
| spelling | doaj.art-480514b01b5a465aab86e57e3b5220542022-12-22T00:15:48ZengIlam University of Medical SciencesJournal of Basic Research in Medical Sciences2383-05062383-09722017-06-01433941Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigenFatemeh Keshavarzi0Parviz Ashtari1Pirooz Ebrahimi2 Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran Sapienza University of Rome, Yas Women Hospital, Tehran Introduction: Toxoplasma gondii (T. gondii) is distributed worldwide and infects most species. The serious incidence and severe or fatal injury caused by T. gondii infection clearly indicates the necessity for the event of a vaccine. The current study goals were to evaluate serological applications of Toxoplasma gondiirhoptry protein 1 (ROP1) antigen. Materials and methods: We created a polymer vaccine by using the eukaryotic plasmid, pROP1. Purification by one-step metal affinity chromatography allowed recovery of milligram amounts of purified recombinant proteins per liter of culture. The quality of this matter for diagnosing of human infections was provided and tested on 77 serum samples which were obtained during routine diagnostic tests. A panel of 20 serum samples from patients with acute toxoplasmosis was compared to a panel of 35 serum samples from individuals with chronic toxoplasmosis. Results: Results of the study indicated that antibodies detected from patients with acute and chronic infections were 96% and 17%, respectively, by using of pROP1 recombinant antigen. Conclusion: According to the present study an immunoglobulin G antibody against ROP1 antigen is made throughout the acute stage of toxoplasmosis infection, but not in the chronic phase of toxoplasmosis.http://jbrms.medilam.ac.ir/browse.php?a_code=A-10-168-2&slc_lang=en&sid=1Toxoplasma gondiiROP1Recombinant antigenAcute toxoplasmosis |
| spellingShingle | Fatemeh Keshavarzi Parviz Ashtari Pirooz Ebrahimi Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen Journal of Basic Research in Medical Sciences Toxoplasma gondii ROP1 Recombinant antigen Acute toxoplasmosis |
| title | Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen |
| title_full | Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen |
| title_fullStr | Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen |
| title_full_unstemmed | Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen |
| title_short | Evaluating the serological applications of Toxoplasma gondii rhoptry protein 1 (ROP1) antigen |
| title_sort | evaluating the serological applications of toxoplasma gondii rhoptry protein 1 rop1 antigen |
| topic | Toxoplasma gondii ROP1 Recombinant antigen Acute toxoplasmosis |
| url | http://jbrms.medilam.ac.ir/browse.php?a_code=A-10-168-2&slc_lang=en&sid=1 |
| work_keys_str_mv | AT fatemehkeshavarzi evaluatingtheserologicalapplicationsoftoxoplasmagondiirhoptryprotein1rop1antigen AT parvizashtari evaluatingtheserologicalapplicationsoftoxoplasmagondiirhoptryprotein1rop1antigen AT piroozebrahimi evaluatingtheserologicalapplicationsoftoxoplasmagondiirhoptryprotein1rop1antigen |